• Medientyp: E-Artikel
  • Titel: Myo-Inositol, Probiotics, and Micronutrient Supplementation From Preconception for Glycemia in Pregnancy: NiPPeR International Multicenter Double-Blind Randomized Controlled Trial
  • Beteiligte: Godfrey, Keith M.; Barton, Sheila J.; El-Heis, Sarah; Kenealy, Timothy; Nield, Heidi; Baker, Philip N.; Chong, Yap Seng; Cutfield, Wayne; Chan, Shiao-Yng; Boyle, Veronica; Cai, Shirong; Carvalho, Ryan; Ann Guiao Castro, Julie; Cavanagh, Mary; Chang, Hsin Fang; Chi, Claudia; Childs, Caroline E.; Chong, Mary F.; Conlon, Cathryn; Cooper, Cyrus; Costello, Paula; Cox, Vanessa; Ebreo, Marilou; Hammond, Judith; [...]
  • Erschienen: American Diabetes Association, 2021
  • Erschienen in: Diabetes Care
  • Sprache: Englisch
  • DOI: 10.2337/dc20-2515
  • ISSN: 0149-5992; 1935-5548
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:sec> <jats:title>OBJECTIVE</jats:title> <jats:p>Better preconception metabolic and nutritional health are hypothesized to promote gestational normoglycemia and reduce preterm birth, but evidence supporting improved outcomes with nutritional supplementation starting preconception is limited.</jats:p> </jats:sec> <jats:sec> <jats:title>RESEARCH DESIGN AND METHODS</jats:title> <jats:p>This double-blind randomized controlled trial recruited from the community 1,729 U.K., Singapore, and New Zealand women aged 18–38 years planning conception. We investigated whether a nutritional formulation containing myo-inositol, probiotics, and multiple micronutrients (intervention), compared with a standard micronutrient supplement (control), taken preconception and throughout pregnancy could improve pregnancy outcomes. The primary outcome was combined fasting, 1-h, and 2-h postload glycemia (28 weeks gestation oral glucose tolerance test).</jats:p> </jats:sec> <jats:sec> <jats:title>RESULTS</jats:title> <jats:p>Between 2015 and 2017, participants were randomized to control (n = 859) or intervention (n = 870); 585 conceived within 1 year and completed the primary outcome (295 intervention, 290 control). In an intention-to-treat analysis adjusting for site, ethnicity, and preconception glycemia with prespecified P &amp;lt; 0.017 for multiplicity, there were no differences in gestational fasting, 1-h, and 2-h glycemia between groups (β [95% CI] loge mmol/L intervention vs. control −0.004 [−0.018 to 0.011], 0.025 [−0.014 to 0.064], 0.040 [0.004–0.077], respectively). Between the intervention and control groups there were no significant differences in gestational diabetes mellitus (24.8% vs. 22.6%, adjusted risk ratio [aRR] 1.22 [0.92–1.62]), birth weight (adjusted β = 0.05 kg [−0.03 to 0.13]), or gestational age at birth (mean 39.3 vs. 39.2 weeks, adjusted β = 0.20 [−0.06 to 0.46]), but there were fewer preterm births (5.8% vs. 9.2%, aRR 0.43 [0.22–0.82]), adjusting for prespecified covariates.</jats:p> </jats:sec> <jats:sec> <jats:title>CONCLUSIONS</jats:title> <jats:p>Supplementation with myo-inositol, probiotics, and micronutrients preconception and in pregnancy did not lower gestational glycemia but did reduce preterm birth.</jats:p> </jats:sec>
  • Zugangsstatus: Freier Zugang